Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03764293 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
A Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC, sponsored by Jiangsu HengRui Medicine Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 543
- Enrollment target
- 20
- Study locations
NCT03764293 is a Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC that has completed, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 543 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT03764293, a Phase 3 study of Locally Advanced or Metastatic and Unresectable HCC, has completed, sponsored by Jiangsu HengRui Medicine Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 543 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG SHR-1210
- DRUG Apatinib
Study Locations (20)
Other
- Cliniques Universitaires de Bruxelles Hopital Erasme - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- UZA - Edegem
- AZ Maria Middelares - Ghent
- AZ Groeninge - Kortrijk
Anhui
- Anhui Provincal Cancer Hospital - Hefei
- Anhui Provincal Hospital - Hefei
- The First Affiliated Hospital Of Anhui Medical University - Hefei
- The Second Affiliated Hospital Of Anhui Medical University - Hefei
California
- Beverly Hills Cancer Center - Beverly Hills
- University of California San Diego (UCSD)-Moores Cancer Center - La Jolla
- University of California - Irvine - Orange
Texas
- The Center for Cancer and Blood Disorders - Fort Worth
- MD Anderson Cancer Center - Houston
- Renovatio Clinical - The Woodlands
Beijing Municipality
- Chinese Academy of Medical Sciences Cancer Hospital - Beijing
- Beijing cancer Hospital - Beijing
- Peking University International Hospital - Beijing
Maryland
- University of Maryland - Baltimore
New York
- Cornell University Weill Cornell Medical College - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 543 participants |
| Start Date | 2019-06-10 |
| Est. Completion | 2023-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03764293
The ClinicalTrials.gov registry entry for NCT03764293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 543 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jiangsu HengRui Medicine Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic and Unresectable HCC appearing as the primary indexed condition, and to 3 interventions - of which Sorafenib is the first listed.
NCT03764293 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Anhui, California.
Frequently Asked Questions
What is clinical trial NCT03764293 about?
NCT03764293 is a clinical study titled "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC". This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced HCC.
What is the current status of trial NCT03764293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 543 participants. The study started on 2019-06-10. Estimated completion is 2023-06-14.
What conditions does trial NCT03764293 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic and Unresectable HCC.
What interventions are being tested in trial NCT03764293?
The interventions under investigation include: Sorafenib (DRUG), SHR-1210 (DRUG), Apatinib (DRUG).
Who is sponsoring clinical trial NCT03764293?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03764293 being conducted?
This trial has 20 study locations across California, Maryland, New York, Texas, Anhui. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.